BR112023017997A2 - Sal ácido cristalino do inibidor de csf-1r, método de preparação do mesmo e uso do mesmo - Google Patents

Sal ácido cristalino do inibidor de csf-1r, método de preparação do mesmo e uso do mesmo

Info

Publication number
BR112023017997A2
BR112023017997A2 BR112023017997A BR112023017997A BR112023017997A2 BR 112023017997 A2 BR112023017997 A2 BR 112023017997A2 BR 112023017997 A BR112023017997 A BR 112023017997A BR 112023017997 A BR112023017997 A BR 112023017997A BR 112023017997 A2 BR112023017997 A2 BR 112023017997A2
Authority
BR
Brazil
Prior art keywords
acid salt
csf
inhibitor
crystalline acid
preparation
Prior art date
Application number
BR112023017997A
Other languages
English (en)
Inventor
Baowei Zhao
Hongping Yu
Lei Zhang
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of BR112023017997A2 publication Critical patent/BR112023017997A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

sal de ácido cristalino do inibidor de csf-1r, e método de preparação do mesmo e uso do mesmo. são fornecidos um sal ácido cristalino de um inibidor de csf-1r e um método de preparação e uso do mesmo, sendo que o inibidor de csf-1r é o composto 3,3-dimetil-n-(6-metil-5-((2-(1-metil-1h-pirazol-4-il)piridin-4-il)oxi)piridin-2-il)-2-oxopirrolidina-1-carboxamida com a estrutura da fórmula (i). o composto de sal ácido cristalino pode melhorar muito as propriedades físico-químicas, como solubilidade, higroscopicidade e estabilidade química do composto de fórmula (i) em um estado livre, e atender aos requisitos de produção industrial e desenvolvimento de preparação de medicamentos clínicos. o composto de sal ácido cristalino pode ser amplamente utilizado na preparação de um medicamento para tratamento de cânceres, tumores, doenças autoimunes, doenças metabólicas ou doenças metastáticas.
BR112023017997A 2021-05-24 2022-05-23 Sal ácido cristalino do inibidor de csf-1r, método de preparação do mesmo e uso do mesmo BR112023017997A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110565750 2021-05-24
PCT/CN2022/094457 WO2022247786A1 (zh) 2021-05-24 2022-05-23 一种结晶型csf-1r抑制剂酸式盐及其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112023017997A2 true BR112023017997A2 (pt) 2023-12-12

Family

ID=84229491

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017997A BR112023017997A2 (pt) 2021-05-24 2022-05-23 Sal ácido cristalino do inibidor de csf-1r, método de preparação do mesmo e uso do mesmo

Country Status (10)

Country Link
EP (1) EP4349827A1 (pt)
JP (1) JP2024518651A (pt)
KR (1) KR20230154956A (pt)
CN (1) CN116848102A (pt)
AU (1) AU2022280839A1 (pt)
BR (1) BR112023017997A2 (pt)
CA (1) CA3211329A1 (pt)
MX (1) MX2023013360A (pt)
TW (1) TW202300142A (pt)
WO (1) WO2022247786A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053992A1 (es) * 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
US9193719B2 (en) * 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145015A2 (en) * 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
SG11201508532VA (en) * 2013-03-15 2015-11-27 Deciphera Pharmaceuticals Llc N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
MX2019014021A (es) 2017-05-24 2020-08-17 Abbisko Therapeutics Co Ltd Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.

Also Published As

Publication number Publication date
WO2022247786A1 (zh) 2022-12-01
EP4349827A1 (en) 2024-04-10
CN116848102A (zh) 2023-10-03
KR20230154956A (ko) 2023-11-09
CA3211329A1 (en) 2022-12-01
TW202300142A (zh) 2023-01-01
JP2024518651A (ja) 2024-05-01
AU2022280839A1 (en) 2023-09-14
MX2023013360A (es) 2023-11-27

Similar Documents

Publication Publication Date Title
EP3299369B1 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
CN105153119B (zh) 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用
CN101255169B (zh) 普拉格雷盐及其制备方法
Sánchez-Lara et al. Decavanadate salts of cytosine and metformin: a combined experimental-theoretical study of potential metallodrugs against diabetes and cancer
CN107108671B (zh) 作为raf激酶抑制剂的化合物和组合物
TW200526208A (en) Substituted benzazoles and methods of their use as inhibitors of Raf kinase
JP5896746B2 (ja) 個別化された抗癌薬としてのプロカスパーゼ活性化化合物の設計、合成および評価
KR101770246B1 (ko) 1-(2-디옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 염
AR029011A1 (es) Tiazoles e imidazo[4,5-b]piridinas, un proceso para su produccion, una composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
EP2719697B1 (en) Pyridonaphthyridine pi3k/mtor dual inhibitors and preparation and use thereof
CN105732615B (zh) Cdk激酶抑制剂
CN102295635A (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
US20150166539A1 (en) Three-ring pi3k and/or mtor inhibitor
CN108078990B (zh) 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途
PE20110147A1 (es) Composicion y proceso - 356
CN109851638A (zh) 取代的二氨基嘧啶化合物
BR112021005750A2 (pt) inibidor de fgfr4 e uso do mesmo
EP3452484B1 (en) Certain protein kinase inhibitors
BR112023017997A2 (pt) Sal ácido cristalino do inibidor de csf-1r, método de preparação do mesmo e uso do mesmo
BRPI0520482A2 (pt) amidas do ácido 4-amino-tieno [3,2-c] piridina-7-carboxìlico
CN108676009A (zh) 作为her2酪氨酸激酶抑制剂的嘧啶衍生物及其应用
CN104203958B (zh) 二环杂环衍生物、其制备及治疗用途
CN107362166A (zh) 四氢吡啶并[4,5‑]噻吩并[2,3‑]嘧啶‑4(3)‑酮类化合物在制药中的应用
CN103483414B (zh) 一种4-氮杂甾体嘌呤核苷类似物及其制备、应用
BR112017000605B1 (pt) Forma policristalina do pró-fármaco de tenofovir, seu método de preparação e seu uso, e composição farmacêutica